Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab
Toshiki Kijima, Hina Yamamoto, Kazutaka Saito, Shota Kusuhara, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Noboru Numao, Yasuyuki Sakai, Nobuaki Matsubara, Takeshi Yuasa, Hitoshi Masuda, Junji Yonese, Yukio Kageyama, Yasuhisa Fujii
Topics & Concepts
MedicinePembrolizumabInternal medicineC-reactive proteinOncologyBiomarkerGastroenterologyBladder cancerCancerImmunotherapyInflammationBiologyBiochemistryBladder and Urothelial Cancer TreatmentsInflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and Biomarkers